Do you want to read an article? Please log in or register.
Message from the new EULAR President and Steering Group
Further Publications Rheumatology
Related content
Further Publications Dermatology
Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group
Br J Dermatol
Schneider R, Reinau D, Stoffel S, Jick SS, Meier CR, Spoendlin J
doi: 10.1111/bjd.19880
SPECIAL REPORT
Rheumatoid Arthritis
EULAR 2021
Systemic Lupus Erythematosus
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease
Arthritis Care Res (Hoboken).
Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, Bacco B, Rubini E, Foddai SG, Padovan M, Gallo Cassarino S, Franceschini F, Andrade D, Benedetto C, Govoni M, Bertero T, Marozio L, Roccatello D, Andreoli L, Sciascia S
doi: 10.1002/acr.24391.
Systemic Lupus Erythematosus
The Performance of the New 2019-EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults
Arthritis Care Res (Hoboken).
Aljaberi N, Nguyen K, Strahle C, Merritt A, Mathur A, Brunner HI
doi: 10.1002/acr.24430.
Systemic Lupus Erythematosus
New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE
Ann Rheum Dis
Whittall Garcia LP, Gladman DD, Urowitz M, Touma Z, Su J, Johnson SR
doi: 10.1136/annrheumdis-2020-218670
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Ann Rheum Dis.
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J
doi: 10.1136/
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
JAMA.
Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE; DUAL-1 Investigators; DUAL-2 Investigators
doi: 10.1001/jama.2016.5258.
Rheumatoid Arthritis
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries
Ann Rheum Dis
Dejaco C, Alunno A, Bijlsma JW, Boonen A, Combe B, Finckh A, Machado PM, Padjen I, Sivera F, Stamm TA, Buttgereit F
doi: 10.1136/annrheumdis-2020-218697
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.